Study guide
10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems
NABP FPGEE Foreign Pharmacy Graduate Equivalency Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Introduction & Exam Overview
1.1 About the FPGEE 1.2 How to Use This Study Guide
2 Chapter 2: Foundational Biomedical Sciences I
2.1 Anatomy 2.2 Physiology 2.3 Biochemistry
3 Chapter 3: Foundational Biomedical Sciences II
3.1 Medical Microbiology 3.2 Immunology 3.3 Pathophysiological Bases of Diseases
4 Chapter 4: Pharmaceutical Calculations, Compounding, and Medicinal Chemistry
4.1 Pharmaceutical Calculations 4.2 Extemporaneous Compounding 4.3 Physicochemical Properties, ADME, and Drug Metabolism Pathways 4.4 Structure-Activity Relationships and Drug-Receptor Interactions
5 Chapter 5: Pharmacology and Toxicology
5.1 Pharmacodynamics and Dose-Response 5.2 Mechanisms of Action of Drugs and Biologics 5.3 Adverse Effects, Side Effects, and Drug Interactions 5.4 Toxicology and Antidotes
6 Chapter 6: Pharmaceutics, Biopharmaceutics, and Pharmacokinetics
6.1 Dosage Forms, Drug Delivery, and Dissolution 6.2 Stability, Shelf-Life, and Manufacturing 6.3 ADME Rates, Half-Lives, and Compartment Models 6.4 Bioavailability, Bioequivalence, Biosimilars, and Pharmacogenomics
7 Chapter 7: Pharmacy Law, Ethics, and Health Care Systems
7.1 Pharmacy Law and Regulations 7.2 Ethics and Regulatory/Oversight Organizations 7.3 US Health Care Systems 7.4 Pharmacoeconomics
8 Chapter 8: Public Health, Practice Management, and Biostatistics
8.1 Pharmacoepidemiology, Population-Based Care, and Public Health 8.2 Practice Management 8.3 Continuous Quality Improvement, Risk Management, and Inventory Control 8.4 Biostatistics and Research Methods
9 Chapter 9: Professional Communication and Behavioral Aspects
9.1 Professional Communication 9.2 Social and Behavioral Aspects of Practice
10 Chapter 10: Clinical Sciences I — Pathophysiology and Patient Assessment
10.1 Clinical Pathophysiology: Cardiovascular and Endocrine 10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems 10.3 Patient Data Collection 10.4 Patient Data Assessment 10.5 Patient-Care Decision Making, Therapy Recommendations, and Education
11 Chapter 11: Clinical Sciences II — Patient Safety, Prevention, and Personalized Care
11.1 Patient Safety: Drug Interactions and Toxicity 11.2 Drug-Induced Disease and Drug Use Disorders 11.3 Disease Prevention 11.4 Personalized Medicine
12 Chapter 12: Clinical Sciences III — Evidence-Based Practice
12.1 Practice Guidelines and Drug Information 12.2 Clinical Trial Evaluation and Information Source Reliability
13 Chapter 13: Clinical Sciences IV — Self-Care and Natural Products
13.1 Self-Care and Natural Products
10.2 Clinical Pathophysiology: Respiratory, GI, Renal, and Other Systems
Key Takeaways Explain This Topic AI
Asthma is Th2-mediated eosinophilic airway inflammation with bronchoconstriction; COPD features persistent airflow limitation from protease-antiprotease imbalance (emphysema) and mucous gland hyperplasia (chronic bronchitis), classified by GOLD groups A-D.
Peptic ulcer disease is dominated by Helicobacter pylori infection and NSAID use; cirrhosis produces portal hypertension (varices, ascites) and hepatic encephalopathy via ammonia and other neurotoxins.
Acute kidney injury is classified as prerenal (perfusion), intrinsic (ATN from ischemia/nephrotoxins or AIN from drug allergy), or postrenal (obstruction); CKD complications include anemia, CKD-MBD, hyperkalemia, and acidosis.
Nephrotic syndrome (heavy proteinuria, edema, hypoalbuminemia) contrasts with nephritic syndrome (hematuria, hypertension, mild proteinuria); distinguishing these guides immunosuppressive and supportive therapy.
Sepsis is a dysregulated host response to infection causing vasodilation, capillary leak, DIC, and multi-organ dysfunction; stroke is ischemic (~85%, thrombotic or embolic) or hemorrhagic, and Parkinson's reflects dopaminergic neuron loss in the substantia nigra.
Last updated: July 2026
- Respiratory Pathophysiology
- Asthma
Asthma is a chronic inflammatory airway disease with Th2-mediated eosinophilic inflammation, bronchoconstriction, mucous hypersecretion, and airway remodeling. Triggers (allergens, exercise, infection, irritants) produce bronchospasm, wheeze, dyspnea, cough. GINA classification (Global Initiative for Asthma) stratifies treatment Steps 1-5 by symptom control and medication intensity — short-acting beta-agonist (SABA) reliever plus inhaled corticosteroid (ICS) controller is the foundation; biologics (omalizumab, mepolizumab, dupilumab) target severe eosinophilic or allergic phenotypes.
COPD
Chronic Obstructive Pulmonary Disease (COPD) features persistent airflow limitation. Emphysema reflects protease-antiprotease imbalance — neutrophil elastase overwhelms alpha-1 antitrypsin, destroying alveolar walls. Chronic bronchitis features chronic productive cough with mucous gland hyperplasia. GOLD classification (Global Initiative for Chronic Obstructive Lung Disease) assigns Groups A-D based on symptoms (mMRC, CAT score) and exacerbation risk; LAMA, LABA, and ICS/LABA combinations form the pharmacologic backbone.
Pneumonia, Pulmonary Embolism, Pulmonary Hypertension
Pneumonia : alveolar infection drives neutrophil exudate and impaired gas exchange; typical (pneumococcal) vs atypical (Mycoplasma, Legionella) patterns. Pulmonary embolism : see Virchow's triad. Pulmonary hypertension : elevated pulmonary arterial pressure with right heart strain ( cor pulmonale ).
- Gastrointestinal Pathophysiology
- GERD
Gastroesophageal reflux disease (GERD) — lower esophageal sphincter (LES) dysfunction permits acid reflux; complications include esophagitis, stricture, Barrett's esophagus (intestinal metaplasia, premalignant), and esophageal adenocarcinoma.
Peptic Ulcer Disease
Peptic ulcer disease (PUD) — Helicobacter pylori infection and NSAID use are the dominant causes. H. pylori urease enables survival in acid and induces mucosal inflammation; NSAIDs inhibit COX-1, depleting protective prostaglandins and mucus. Zollinger-Ellison syndrome (gastrin-secreting tumor) causes refractory multiple ulcers.
Inflammatory Bowel Disease
Inflammatory bowel disease (IBD) comprises Crohn's disease (transmural inflammation, skip lesions, any GI segment) and ulcerative colitis (mucosal inflammation, continuous from rectum). Immune dysregulation with TNF-alpha, IL-12/23 drives chronic inflammation; biologics (infliximab, adalimumab, ustekinumab, vedolizumab) target these cytokines.
IBS, Liver Disease, Pancreatitis
Irritable bowel syndrome (IBS) is a functional disorder (no inflammation) with pain related to defecation and altered bowel habit (Bristol scale). Cirrhosis — fibrosis and nodular regeneration from chronic injury (Hepatitis B/C, alcohol, NAFLD); portal hypertension produces varices, ascites, splenomegaly; hepatic encephalopathy arises when ammonia and other neurotoxins cross the blood-brain barrier. Pancreatitis features premature zymogen activation, autodigestion, and systemic inflammatory response.
- Renal Pathophysiology
- Acute Kidney Injury
Acute kidney injury (AKI) is classified as prerenal (decreased renal perfusion — hypovolemia, heart failure, sepsis), intrinsic ( acute tubular necrosis (ATN) from ischemia or nephrotoxins such as contrast, aminoglycosides, cisplatin; acute interstitial nephritis (AIN) from allergic drug reaction — beta-lactams, NSAIDs, PPIs), or postrenal (urinary obstruction — BPH, stones, tumor).
Chronic Kidney Disease
Chronic kidney disease (CKD) is progressive nephron loss over ≥3 months. Complications: anemia (reduced erythropoietin), chronic kidney disease-mineral and bone disorder (CKD-MBD) — phosphate retention, reduced calcitriol, secondary hyperparathyroidism, renal osteodystrophy; hyperkalemia, metabolic acidosis, fluid overload, uremic symptoms, accelerated cardiovascular disease.
Nephrotic vs Nephritic Syndromes
Nephrotic syndrome : heavy proteinuria (>3.5 g/day), hypoalbuminemia, edema, hyperlipidemia — minimal change disease, membranous nephropathy, focal segmental glomerulosclerosis. Nephritic syndrome : hematuria, hypertension, mild proteinuria, azotemia — post-streptococcal glomerulonephritis, IgA nephropathy, rapidly progressive GN.
- System Disease Key Pathophysiology Representative Drugs
- Respiratory Asthma Th2 eosinophilic inflammation, bronchoconstriction ICS, LABA, LTRA, biologics
- Respiratory COPD Protease-antiprotease imbalance, airflow limitation LAMA, LABA, ICS/LABA
- GI PUD H. pylori, NSAID prostaglandin depletion PPI + clarithromycin + amoxicillin; PPI
- GI IBD (Crohn's) Transmural Th1/Th17 inflammation, TNF-alpha Corticosteroids, anti-TNF, anti-IL12/23
- Renal AKI (ATN) Tubular epithelial injury, ischemia/nephrotoxin Nephrotoxin avoidance, supportive care
- Renal CKD-MBD Phosphate retention, low calcitriol, high PTH Phosphate binders, calcimimetic, vitamin D analog
Neurologic Parkinson's Dopaminergic neuron loss in substantia nigra Levodopa/carbidopa, MAO-B, dopamine agonists
- Rheumatologic Gout Monosodium urate crystal deposition NSAIDs, colchicine, allopurinol, febuxostat
- Other Systems
- Neurologic
Stroke — ischemic (thrombotic or embolic occlusion, ~85% of cases) vs hemorrhagic (intracerebral, subarachnoid). Seizure disorders — focal vs generalized, from abnormal synchronous neuronal discharge; etiologies include structural, metabolic, infectious, genetic. Parkinson's disease — degeneration of dopaminergic neurons in the substantia nigra pars compacta producing bradykinesia, rigidity, resting tremor, postural instability. Alzheimer's disease — amyloid-beta plaques, tau neurofibrillary tangles, and cholinergic deficit producing progressive memory and cognitive decline.
Rheumatologic
Rheumatoid arthritis (RA) — autoimmune synovitis with anti-cyclic citrullinated peptide (anti-CCP) antibodies and joint destruction; treated with DMARDs (methotrexate), biologics (anti-TNF, anti-IL6), JAK inhibitors. Osteoarthritis — mechanical cartilage degradation with secondary inflammation. Gout — monosodium urate crystal deposition in joints; acute (NSAIDs, colchicine, glucocorticoids) vs chronic (allopurinol, febuxostat, pegloticase). Systemic lupus erythematosus (SLE) — multi-system autoimmunity with ANA, anti-dsDNA, anti-Smith antibodies; nephritis, malar rash, photosensitivity.
Infectious Disease and Sepsis
Sepsis is a dysregulated host response to infection causing vasodilation, capillary leak, disseminated intravascular coagulation (DIC), and multi-organ dysfunction. The qSOFA score (RR ≥22, altered mentation, SBP ≤100) screens for likely septic patients outside the ICU; lactate ≥2 mmol/L reflects tissue hypoperfusion and guides fluid resuscitation. Septic shock is sepsis with persistent hypotension requiring vasopressors despite adequate volume, with mortality exceeding 30%. Common infections by system: respiratory (pneumococcal, influenza, COVID), genitourinary (UTI, pyelonephritis), gastrointestinal (C. difficile, Salmonella, Campylobacter), skin and soft tissue (cellulitis, S. aureus, streptococcus), bloodstream (endocarditis, central line infection). Early antibiotics (within 1 hour of recognition), source control, and hemodynamic support with crystalloids and norepinephrine are foundational; vancomycin plus piperacillin-tazobactam is a common empiric broad regimen pending cultures.